140 related articles for article (PubMed ID: 22689211)
21. A case of childhood T cell acute lymphoblastic leukemia with a complex t(9;9) and homozygous deletion of CDKN2A gene associated with a Philadelphia-positive minor subclone.
Ney-Garcia DR; Vieira TP; Liehr T; Bhatt S; de Souza MT; de Figueiredo AF; Ribeiro RC; Silva ML
Blood Cells Mol Dis; 2013 Feb; 50(2):131-3. PubMed ID: 23044159
[No Abstract] [Full Text] [Related]
22. Dasatinib (Sprycel) for CML and Ph + ALL.
Med Lett Drugs Ther; 2007 Jan; 49(1252):6-7. PubMed ID: 17220814
[No Abstract] [Full Text] [Related]
23. Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment.
Yeung DT; Moulton DJ; Heatley SL; Nievergall E; Dang P; Braley J; Branford S; Moore S; Mullighan CG; Hughes TP; White DL
Leukemia; 2015 Jan; 29(1):230-2. PubMed ID: 25179732
[No Abstract] [Full Text] [Related]
24. Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.
Sonmez M; Cobanoglu U; Ovali E; Omay SB
J Clin Pharm Ther; 2008 Jun; 33(3):329-30. PubMed ID: 18452422
[No Abstract] [Full Text] [Related]
25. Dasatinib-induced response in a rare case of chronic lymphocytic leukaemia associated with chronic myeloid leukaemia.
Tecchio C; Nichele I; Todeschini G; Pizzolo G; Ambrosetti A
Br J Haematol; 2009 Jul; 146(2):222-3. PubMed ID: 19466973
[No Abstract] [Full Text] [Related]
26. Management of Bcr-Abl-positive leukemias with dasatinib.
Hochhaus A
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1529-36. PubMed ID: 18020922
[TBL] [Abstract][Full Text] [Related]
27. Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia.
Ernst T; Score J; Deininger M; Hidalgo-Curtis C; Lackie P; Ershler WB; Goldman JM; Cross NC; Grand F
Br J Haematol; 2011 Apr; 153(1):43-6. PubMed ID: 21391972
[TBL] [Abstract][Full Text] [Related]
28. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
29. Dasatinib: for some difficult cases of adult leukaemia.
Prescrire Int; 2008 Aug; 17(96):149-50. PubMed ID: 19496239
[No Abstract] [Full Text] [Related]
30. Advances in the Genetics and Therapy of Acute Lymphoblastic Leukemia.
Chiaretti S; Gianfelici V; O'Brien SM; Mullighan CG
Am Soc Clin Oncol Educ Book; 2016; 35():e314-22. PubMed ID: 27249738
[TBL] [Abstract][Full Text] [Related]
31. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
32. T-cell acute lymphoblastic leukemia associated with complex karyotype and SET-NUP214 rearrangement: a case study and review of the literature.
Lee SG; Park TS; Cho SY; Lim G; Park GJ; Oh SH; Cho EH; Chong SY; Huh JY
Ann Clin Lab Sci; 2011; 41(3):267-72. PubMed ID: 22075511
[TBL] [Abstract][Full Text] [Related]
33. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia.
Graux C; Cools J; Melotte C; Quentmeier H; Ferrando A; Levine R; Vermeesch JR; Stul M; Dutta B; Boeckx N; Bosly A; Heimann P; Uyttebroeck A; Mentens N; Somers R; MacLeod RA; Drexler HG; Look AT; Gilliland DG; Michaux L; Vandenberghe P; Wlodarska I; Marynen P; Hagemeijer A
Nat Genet; 2004 Oct; 36(10):1084-9. PubMed ID: 15361874
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy.
Richebourg S; Eclache V; Perot C; Portnoi MF; Van den Akker J; Terré C; Maareck O; Soenen V; Viguié F; Laï JL; Andrieux J; Corm S; Roche-Lestienne C;
Cancer Genet Cytogenet; 2008 Apr; 182(2):95-102. PubMed ID: 18406870
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG
Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800
[TBL] [Abstract][Full Text] [Related]
36. New approved dasatinib regimen available for clinical use.
Snyder DS
Expert Rev Anticancer Ther; 2009 Mar; 9(3):285-92. PubMed ID: 19275507
[TBL] [Abstract][Full Text] [Related]
37. Prognostic relevance of TLX3 (HOX11L2) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing early and late re-intensification elements.
Attarbaschi A; Pisecker M; Inthal A; Mann G; Janousek D; Dworzak M; Pötschger U; Ullmann R; Schrappe M; Gadner H; Haas OA; Panzer-Grümayer R; Strehl S;
Br J Haematol; 2010 Jan; 148(2):293-300. PubMed ID: 19821827
[TBL] [Abstract][Full Text] [Related]
38. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
39. Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
Ault P
Clin J Oncol Nurs; 2007 Feb; 11(1):125-9. PubMed ID: 17441403
[TBL] [Abstract][Full Text] [Related]
40. [Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia].
Bjerrum OW; Dufva IH; Stentoft J; Hasselbalch HC
Ugeskr Laeger; 2008 Jan; 170(5):331-3. PubMed ID: 18252160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
